Lexeo Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2022 to 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Lexeo Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2022 to 2024.
  • Lexeo Therapeutics, Inc. Operating Income (Loss) for the quarter ending December 31, 2024 was -$27.4M, a 82.9% decline year-over-year.
  • Lexeo Therapeutics, Inc. Operating Income (Loss) for the twelve months ending December 31, 2024 was -$106M, a 54.4% decline year-over-year.
  • Lexeo Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$106M, a 54.4% decline from 2023.
  • Lexeo Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$68.5M, a 13.2% decline from 2022.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$106M -$37.3M -54.4% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-24
2023 -$68.5M -$8M -13.2% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-24
2022 -$60.5M Jan 1, 2022 Dec 31, 2022 10-K 2024-03-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.